Doubt they will get EUA since _老虎社区_美港股上老虎

2021-06-14

Doubt they will get EUA since most American are already vaccinated with MRNA from BioNTech and Moderna? For normal approval from FDA, it should take up till 2022?

Novavax Soars As Its COVID-19 Vaccine Is Found 90% Effective, To Seek FDA OK

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":184387625,"tweetId":"184387625","gmtCreate":1623684659667,"gmtModify":1631884244855,"author":{"id":3570768873457401,"idStr":"3570768873457401","authorId":3570768873457401,"authorIdStr":"3570768873457401","name":"BlessedCyrus","avatar":"https://static.tigerbbs.com/eb301da67b54f9fd5d2fd2626595aada","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Doubt they will get EUA since most American are already vaccinated with MRNA from BioNTech and Moderna? For&nbsp;normal approval from FDA, it should take up till 2022?&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Doubt they will get EUA since most American are already vaccinated with MRNA from BioNTech and Moderna? For&nbsp;normal approval from FDA, it should take up till 2022?&nbsp;</p></body></html>","text":"Doubt they will get EUA since most American are already vaccinated with MRNA from BioNTech and Moderna? For normal approval from FDA, it should take up till 2022?","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/184387625","repostId":2143609782,"repostType":2,"repost":{"id":"2143609782","kind":"news","pubTimestamp":1623669938,"share":"https://www.laohu8.com/m/news/2143609782?lang=&edition=full","pubTime":"2021-06-14 19:25","market":"us","language":"en","title":"Novavax Soars As Its COVID-19 Vaccine Is Found 90% Effective, To Seek FDA OK","url":"https://stock-news.laohu8.com/highlight/detail?id=2143609782","media":"Investing.com","summary":"Investing.com -- Novavax (NASDAQ:NVAX) shares rose more than 10% in Monday’s premarket trading after","content":"<p>Investing.com -- Novavax (NASDAQ:NVAX) shares rose more than 10% in Monday’s premarket trading after the company said a phase-three trial had found its two-dose COVID-19 vaccine to be 90.4% effective.</p>\n<p>The trial had 29,960 participants across the U.S. and Mexico.</p>\n<p>The vaccine was found to be 100% effective in preventing moderate and severe infections and 93% effective against some variants, Novavax said. The company plans to file for approval with the Food and Drug Administration in the third quarter.</p>\n<p>Upon regulatory approvals, Novavax remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021, the company said in a release.</p>\n<p>Once authorized, the Novavax vaccine would join Pfizer BioNTech (NYSE:PFE) (NASDAQ:BNTX), Moderna (NASDAQ:MRNA) and Johnson&amp;Johnson (NYSE:JNJ), the three COVID-19 shots already approved for emergency use in the U.S.</p>\n<p>Barring J&amp;J’s, all are two-dose vaccines.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Soars As Its COVID-19 Vaccine Is Found 90% Effective, To Seek FDA OK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Soars As Its COVID-19 Vaccine Is Found 90% Effective, To Seek FDA OK\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavax-soars-covid-19-vaccine-063438092.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com -- Novavax (NASDAQ:NVAX) shares rose more than 10% in Monday’s premarket trading after the company said a phase-three trial had found its two-dose COVID-19 vaccine to be 90.4% effective....</p>\n\n<a href=\"https://finance.yahoo.com/news/novavax-soars-covid-19-vaccine-063438092.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","JNJ":"强生"},"source_url":"https://finance.yahoo.com/news/novavax-soars-covid-19-vaccine-063438092.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143609782","content_text":"Investing.com -- Novavax (NASDAQ:NVAX) shares rose more than 10% in Monday’s premarket trading after the company said a phase-three trial had found its two-dose COVID-19 vaccine to be 90.4% effective.\nThe trial had 29,960 participants across the U.S. and Mexico.\nThe vaccine was found to be 100% effective in preventing moderate and severe infections and 93% effective against some variants, Novavax said. The company plans to file for approval with the Food and Drug Administration in the third quarter.\nUpon regulatory approvals, Novavax remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021, the company said in a release.\nOnce authorized, the Novavax vaccine would join Pfizer BioNTech (NYSE:PFE) (NASDAQ:BNTX), Moderna (NASDAQ:MRNA) and Johnson&Johnson (NYSE:JNJ), the three COVID-19 shots already approved for emergency use in the U.S.\nBarring J&J’s, all are two-dose vaccines.","news_type":1},"isVote":1,"tweetType":1,"viewCount":496,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["AMSWA","AXP","AFG"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":135,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/184387625"}